PyAOPCAS# 156311-83-0 |
2D Structure
- BS-181
Catalog No.:BCC1439
CAS No.:1092443-52-1
- CDK inhibitor II
Catalog No.:BCC1464
CAS No.:1269815-17-9
- CGP60474
Catalog No.:BCC1474
CAS No.:164658-13-3
- SNS-032 (BMS-387032)
Catalog No.:BCC1152
CAS No.:345627-80-7
- Dinaciclib (SCH727965)
Catalog No.:BCC3765
CAS No.:779353-01-4
- AT7519
Catalog No.:BCC2541
CAS No.:844442-38-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 156311-83-0 | SDF | Download SDF |
PubChem ID | 11038641 | Appearance | Powder |
Formula | C17H27F6N7OP2 | M.Wt | 521.38 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in water or 1% acetic acid | ||
Chemical Name | tripyrrolidin-1-yl(triazolo[4,5-b]pyridin-3-yloxy)phosphanium;hexafluorophosphate | ||
SMILES | C1CCN(C1)[P+](N2CCCC2)(N3CCCC3)ON4C5=C(C=CC=N5)N=N4.F[P-](F)(F)(F)(F)F | ||
Standard InChIKey | CBZAHNDHLWAZQC-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H27N7OP.F6P/c1-2-11-21(10-1)26(22-12-3-4-13-22,23-14-5-6-15-23)25-24-17-16(19-20-24)8-7-9-18-17;1-7(2,3,4,5)6/h7-9H,1-6,10-15H2;/q+1;-1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
PyAOP Dilution Calculator
PyAOP Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.918 mL | 9.5899 mL | 19.1799 mL | 38.3597 mL | 47.9497 mL |
5 mM | 0.3836 mL | 1.918 mL | 3.836 mL | 7.6719 mL | 9.5899 mL |
10 mM | 0.1918 mL | 0.959 mL | 1.918 mL | 3.836 mL | 4.795 mL |
50 mM | 0.0384 mL | 0.1918 mL | 0.3836 mL | 0.7672 mL | 0.959 mL |
100 mM | 0.0192 mL | 0.0959 mL | 0.1918 mL | 0.3836 mL | 0.4795 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PyAOP
- GTS 21 dihydrochloride
Catalog No.:BCC7948
CAS No.:156223-05-1
- Hispidulin 7-O-neohesperidoside
Catalog No.:BCN2952
CAS No.:156186-00-4
- CEP 1347
Catalog No.:BCC7982
CAS No.:156177-65-0
- Maackiaflavanone
Catalog No.:BCN6834
CAS No.:156162-10-6
- BQ-788 sodium salt
Catalog No.:BCC5151
CAS No.:156161-89-6
- Lys-γ3-MSH
Catalog No.:BCC6049
CAS No.:156159-18-1
- SGC 0946
Catalog No.:BCC2216
CAS No.:1561178-17-3
- Alvimopan
Catalog No.:BCC1347
CAS No.:156053-89-3
- Qianhucoumarin E
Catalog No.:BCN3506
CAS No.:156041-02-0
- Angelidiol
Catalog No.:BCN7964
CAS No.:156009-77-7
- H-HoArg-OH
Catalog No.:BCC3226
CAS No.:156-86-5
- Sodium butyrate
Catalog No.:BCC4720
CAS No.:156-54-7
- 11-Anhydro-16-oxoalisol A
Catalog No.:BCN7703
CAS No.:156338-93-1
- Ehretioside B
Catalog No.:BCN1703
CAS No.:156368-84-2
- Ailanthoidol
Catalog No.:BCN7705
CAS No.:156398-61-7
- 3,4-Seco-3-oxobisabol-10-ene-4,1-olide
Catalog No.:BCN7550
CAS No.:1564265-85-5
- CWHM-12
Catalog No.:BCC5548
CAS No.:1564286-55-0
- cis-Khellactone
Catalog No.:BCN3703
CAS No.:15645-11-1
- α-Conotoxin ImI
Catalog No.:BCC5974
CAS No.:156467-85-5
- Myricetin 3-O-galactoside
Catalog No.:BCN4703
CAS No.:15648-86-9
- 1-Hydroxytropacocaine
Catalog No.:BCN1919
CAS No.:156497-23-3
- 7,13-Dideacetyl-9,10-didebenzoyltaxchinin C
Catalog No.:BCN7670
CAS No.:156497-25-5
- Ryanodine
Catalog No.:BCC5742
CAS No.:15662-33-6
- Cisplatin
Catalog No.:BCN1552
CAS No.:14283-03-5
Orthogonal chemistry for the synthesis of thiocoraline-triostin hybrids. Exploring their structure-activity relationship.[Pubmed:23746132]
J Med Chem. 2013 Jul 11;56(13):5587-600.
The natural compounds triostin and thiocoraline are potent antitumor agents that act as DNA bisintercalators. From a pharmaceutical point of view, these compounds are highly attractive although they present a low pharmacokinetic profile, in part due to their low solubility. Synthetically, they represent a tour de force because no robust strategies have been developed to access a broad range of these bicyclic (depsi)peptides in a straightforward manner. Here we describe solid-phase strategies to synthesize new bisintercalators, such as thiocoraline-triostin hybrids, as well as analogues bearing soluble tags. Orthogonal protection schemes (up to five from: Fmoc, Boc Alloc, pNZ, o-NBS, and Troc), together with the right concourse of the coupling reagents (HOSu, HOBt, HOAt, Oxyma, EDC, DIPCDI, PyAOP, PyBOP, HATU, COMU), were crucial to establish the synthetic plan. In vitro studies and structure-activity relationships have been shown trends in the structure-activity relationship that will facilitate the design of new bisintercalators.
Facile solid-phase parallel synthesis of linear and cyclic peptoids for comparative studies of biological activity.[Pubmed:25602927]
ACS Comb Sci. 2015 Mar 9;17(3):196-201.
A series of linear and cyclic peptoids, which were expected to possess better pharmacokinetic properties and biological activities for blocking the interaction between apolipoprotein E and amyloid-beta, were designed and synthesized as possible therapeutic agents. Peptoids were easily synthesized on solid-phase by the submonomer strategy and polar side chain-containing amines were effectively introduced under the modified reaction conditions. For the synthesis of cyclic peptoids, beta-alanine protected with the 2-phenylisopropyl group, which could be selectively removed by 2% TFA, was used as a primary amine to afford a complete peptoid unit. The macrolactamization between the carboxylic acid of beta-alanine moiety and terminal amine of peptoids was successfully performed in the presence of the PyAOP coupling agent on solid-phase in all the cases, providing various sizes of cyclic peptoids. In particular, some cyclic peptoids prepared in this study are the largest in size among cyclic peptoids reported to date. The synthetic strategy which was adopted in this study can also provide a robust platform for solid-phase construction of cyclic peptoid libraries. Currently, synthetic peptoids have been used to test interesting biological activities including the ApoE/Abeta interaction inhibition, nontoxicity, the blood-brain barrier permeability, etc.
A novel bis(pinacolato)diboron-mediated N-O bond deoxygenative route to C6 benzotriazolyl purine nucleoside derivatives.[Pubmed:27377367]
Org Biomol Chem. 2016 Aug 7;14(29):7069-83.
Reaction of amide bonds in t-butyldimethylsilyl-protected inosine, 2'-deoxyinosine, guanosine, 2'-deoxyguanosine, and 2-phenylinosine with commercially available peptide-coupling agents (benzotriazol-1H-yloxy)tris(dimethylaminophosphonium) hexafluorophosphate (BOP), (6-chloro-benzotriazol-1H-yloxy)trispyrrolidinophosphonium hexafluorophosphate (PyClocK), and (7-azabenzotriazol-1H-yloxy)trispyrrolidinophosphonium hexafluorophospate (PyAOP) gave the corresponding O(6)-(benzotriazol-1-yl) nucleoside analogues containing a C-O-N bond. Upon exposure to bis(pinacolato)diboron and base, the O(6)-(benzotriazol-1-yl) and O(6)-(6-chlorobenzotriazol-1-yl) purine nucleoside derivatives obtained from BOP and PyClocK, respectively, underwent N-O bond reduction and C-N bond formation, leading to the corresponding C6 benzotriazolyl purine nucleoside analogues. In contrast, the 7-azabenzotriazolyloxy purine nucleoside derivatives did not undergo efficient deoxygenation, but gave unsymmetrical nucleoside dimers instead. This is consistent with a prior report on the slow reduction of 1-hydroxy-1H-4-aza and 1-hydroxy-1H-7-azabenzotriazoles. Because of the limited number of commercial benzotriazole-based peptide coupling agents, and to show the applicability of the method when such coupling agents are unavailable, 1-hydroxy-1H-5,6-dichlorobenzotriazole was synthesized. Using this compound, silyl-protected inosine and 2'-deoxyinosine were converted to the O(6)-(5,6-dichlorobenzotriazol-1-yl) derivatives via in situ amide activation with PyBroP. The O(6)-(5,6-dichlorobenzotriazol-1-yl) purine nucleosides so obtained also underwent smooth reduction to afford the corresponding C6 5,6-dichlorobenzotriazolyl purine nucleoside derivatives. A total of 13 examples were studied with successful reactions occurring in 11 cases (the azabenzotriazole derivatives, mentioned above, being the only unreactive entities). To understand whether these reactions are intra or intermolecular processes, a crossover experiment was conducted. The results of this experiment as well as those from reactions conducted in the absence of bis(pinacolato)diboron and in the presence of water indicate that detachment of the benzotriazoloxy group from the nucleoside likely occurs, followed by reduction, and reattachment of the ensuing benzotriazole, leading to products.
Methylamidation for sialoglycomics by MALDI-MS: a facile derivatization strategy for both alpha2,3- and alpha2,6-linked sialic acids.[Pubmed:20831242]
Anal Chem. 2010 Oct 1;82(19):8300-6.
Neutralization of carboxylic acid is an important means to avoid sialic acid dissociation when sialylated glycans are analyzed by matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS). In this paper, we describe a simple and rapid method to modify the sialic acids of sialylated glycans in the presence of methylamine and (7-azabenzotriazol-1-yloxy) trispyrrolidinophosphonium hexafluorophosphate (PyAOP). After methylamidation, sialylated glycans can be analyzed by MALDI-MS without loss of the sialic acid moiety. The electrospray ionization mass spectrometry (ESI-MS) and MALDI-MS analysis of both 3'- and 6'-sialyllactose derivatives indicated that the quantitative conversion of sialic acids was achieved, regardless of their linkage types. This derivatization strategy was further validated with the N-glycans released from three standard glycoproteins (fetuin, human acid glycoprotein, and bovine acid glycoprotein) containing different types of complex glycans. Most importantly, this derivatization method enabled the successful characterization of N-glycans of sera from different species (human, mouse, and rat) by MALDI-MS. Because of the mild reaction conditions, the modification in sialic acid residues can be retained. This improvement makes it possible to detect sialylated glycans containing O-acetylated sialic acid moieties using MALDI-MS in positive-ion mode.
In-depth structural characterization of N-linked glycopeptides using complete derivatization for carboxyl groups followed by positive- and negative-ion tandem mass spectrometry.[Pubmed:24773001]
Anal Chem. 2014 Jun 3;86(11):5360-9.
Tandem mass spectrometry (MS/MS or MS(n)) is a powerful tool for characterizing N-linked glycopeptide structures. However, it is still difficult to obtain detailed structural information on the glycan moiety directly from glycopeptide ions. Here, we propose a new method for in-depth analysis of the glycopeptide structure using MS/MS. This method involves complete derivatization of carboxyl groups in glycopeptides. Methylamidation using PyAOP as a condensing reagent has been optimized for derivatizing all carboxyl groups in glycopeptides. By derivatizing carboxyl groups on the peptide moiety (i.e., Asp, Glu, and C-terminus), the glycopeptides efficiently produce informative glycan fragment ions, including the nonreducing end of the glycan moiety under negative-ion collision-induced dissociation (CID) conditions. These glycan fragment ions can define detailed structural features on the glycan moiety (e.g., the specific composition of the two antennae, the location of fucose residues, and the presence/absence of bisecting GlcNAc residues). For sialylated glycopeptides, carboxyl groups on sialic acid residues are simultaneously derivatized using methylamidation, suppressing preferential loss of residues during MS analysis. As a result, both sialylated and nonsialylated glycopeptides can be analyzed in the same manner. Positive-ion CID of methylamine-derivatized glycopeptides mainly provides information on peptide sequence and glycan composition, whereas negative-ion CID provides in-depth structural information on the glycan moiety. The derivatization step can be readily incorporated into conventional pretreatment for glycopeptide MS analysis without loss of sensitivity, making derivatization suitable for practical use.